Sarcoma patients' significant symptom burden negatively impacts quality of life
the ONA take:
Adult patients with sarcoma experience a significant physiological and psychological symptom burden, which has a strong negative impact on health-related quality of life (HRQoL), with numerous physiological symptoms undertreated with medications, a study published in the journal Supportive Care in Cancer has shown.
For the study, researchers evaluated 79 patients with sarcoma in order to evaluate how symptom burden affects HRQoL and medication use. Most patients were diagnosed with stromal tumor, while some had leiomyosarcoma and liposarcoma.
Results showed that the most common physical symptoms experienced by patients were tiredness, lack of energy, and difficulty sleeping, while the most prevalent psychological symptoms were irritability, worrying, and anxiety.
Researchers found that 33.0% of patients reported difficulty sleeping, but only 6.3% of all patients received hypnotics.
Similarly, only 1.3% of all patients received appetite stimulants while 27.9% of patients reported experiencing lack of appetite.
Adult patients with sarcoma experience significant symptom burden, which has a strong negative impact on health-related quality of life.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|